Sanofi to 'rebuild trust' with Regeneron; Apnimed adds to string of 'upsized' biotech IPOs
Sanofi to 'rebuild trust' with Regeneron; Apnimed adds to string of 'upsized' biotech IPOs
Sanofi
Sanofi (NASDAQ: SNY; Euronext: SAN) is a global biopharmaceutical company with major franchises in immunology (Dupixent, partnered with Regeneron), vaccines (Beyfortus, Fluzone, Dengvaxia), rare disease (Genzyme-legacy Pompe, Fabry, MS), and a growing oncology pipeline. Sanofi has been reshaping its R&D portfolio toward immunology and rare disease while spinning off its consumer health unit.
Company Info
Sector:Diversified Biopharmaceuticals
Headquarters:Paris, France
Founded:1973
Website:www.sanofi.com/en
Recent News
Sanofi asked to change Dupixent ads after Galderma challenge
Sanofi has been asked to change its Dupixent advertising after a challenge from Galderma over the campaign's claims.
Sanofi pauses mid-stage lung study amid new CEO's 'rigorous portfolio prioritization'
Sanofi has paused a mid-stage chronic lung disease study as new CEO Belen Garijo applies rigorous portfolio prioritization to the pipeline.
Sanofi suspends chronic lung disease phase 2 study
Sanofi suspends chronic lung disease phase 2 study
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
Sanofi drug pipeline worries, Dupixent dependence shake shares
Sanofi drug pipeline worries, Dupixent dependence shake shares
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
Sanofi gets FDA untitled letter over Beyfortus promotional emails
Sanofi receives an FDA untitled letter calling out Beyfortus (nirsevimab) promotional emails as misleading.
Sanofi reprimanded for disparaging Pfizer's RSV vaccine
Sanofi was reprimanded for disparaging Pfizer's RSV vaccine in marketing materials.
Sanofi announces limited changes to its revamped executive team
Sanofi made limited changes to its executive team as new CEO Garijo settles in.
Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine
Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine (reported by Reuters)
Sanofi unit in Ireland dinged by FDA on Altuviiio production
Sanofi unit in Ireland dinged by FDA on Altuviiio production. (Fierce Pharma.)
Sanofi’s Pompe disease treatment successor passes Phase 3 test in babies
Sanofi’s Pompe disease treatment successor passes Phase 3 test in babies — Endpoints News coverage of biopharma industry developments.
Sanofi R&D leader Houman Ashrafian to depart, Paulo Fontoura to take the reins
Sanofi's head of R&D Houman Ashrafian will leave the company, with Paulo Fontoura tapped to succeed him as Sanofi reshapes its research leadership.
Sofinnova, Sanofi alum unveil Bionyra with $165M and next-gen immunology assets
Formed by Sofinnova Partners and former Sanofi executive Frédéric Marrache, Bionyra Pharma emerged from stealth Monday with an initial focus in inflammatory bowel disease and atopic dermatitis.
Leadership Team
Belén Garijo
Chief Executive Officer
Careers & Job Openings